Modified FOLFOX6 (mFOLFOX6) in metastatic colorectal carcinoma patients with poor performance status

Tomohiro Nishi, Yasuo Hamamoto, Junko Uemoto, Kei Onodera, Etsuko Warita, Yasuhiro Yamanaka

Research output: Contribution to journalArticle

1 Citation (Scopus)


Because mFOLFOX6 has few contraindications, it is useful for poor performance status (PS) cases. However, in Japan, there are some reports that the dose is reduced easily. We retrospectively examined the safety/usefulness of the full dose mFOLFOX6 (first-line) for advanced colon cancer patients with poor PS. Four of five cases had improved PS. The response rate was 60%. Grade 3/4 adverse events were infection, leukopenia, and neutropenia. Treatment-related deaths within 60 days of starting treatment were absent. Full-dose mFOLFOX6 for poor PS may be beneficial. However, we must consider the increased risk of adverse events.

Original languageEnglish
Pages (from-to)2557-2560
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Issue number13
Publication statusPublished - 2012 Dec



  • Palliative chemotherapy
  • Poor performance status

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this